Key statistics dashboard for Biodesix, Inc. (BDSX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways.
Stock Data
| Price | $28.56 |
| Market Cap | $232M |
| Beta | 0.57 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -8.74 |
| Price / Book | 31.19 |
| P/S | 2.19 |
| P/FCF | -11.05 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 82.50% |
| EBIT Margin | -19.30% |
| EBITDA Margin | -13.87% |
| Operating Margin | -20.01% |
| Net Margin | -26.97% |
Financial Health
| Current Ratio | 2.85 |
| Quick Ratio | 2.85 |
| Cash Ratio | 1.96 |
| Debt / Equity | 7.85 |
| Debt / Assets | 75.32% |
| Interest Coverage | -2.54 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -7.45 |
Per-Share Data
| Revenue per share | 10.00 |
| Book Value per share | 0.89 |
| Cash per share | 2.91 |
| FCF per share | -1.98 |
| Tangible Book Value per share | -0.86 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.86 |
Related companies: ALGS · INMB · MRSN · NOTV · OKUR · PDSB · SKYE
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BDSX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks